We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+14.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$949M
AUM Growth
+$37.8M
Cap. Flow
-$30.5M
Cap. Flow %
-3.21%
Top 10 Hldgs %
31.29%
Holding
98
New
10
Increased
21
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$34M
2
ZBH icon
Zimmer Biomet
ZBH
+$18.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.6M
4
ISRG icon
Intuitive Surgical
ISRG
+$10.3M
5
PRCT icon
Procept Biorobotics
PRCT
+$9.22M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$21.9M
2
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$8.61M
3
THC icon
Tenet Healthcare
THC
+$8.54M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$8.33M
5
UNH icon
UnitedHealth
UNH
+$7.82M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Industrials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALHC icon
51
Alignment Healthcare
ALHC
$2.86B
$5.75M 0.61%
1,000,000
– –
XNCR icon
52
Xencor
XNCR
$1.6B
$5.62M 0.59%
225,000
-25,000
-10% -$680K
RCM
53
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.54M 0.58%
300,000
– –
MRNA icon
54
Moderna
MRNA
$23.9B
$5.47M 0.58%
+45,000
New +$6M
IMCR icon
55
Immunocore
IMCR
$1.73B
$5.35M 0.56%
89,278
-42,010
-32% -$2.4M
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.06M 0.53%
140,000
-75,000
-35% -$3.09M
INSP icon
57
Inspire Medical Systems
INSP
$1.73B
$5M 0.53%
15,400
-22,992
-60% -$6.57M
RPRX icon
58
Royalty Pharma
RPRX
$25.8B
$4.61M 0.49%
150,000
-15,000
-9% -$508K
EVH icon
59
Evolent Health
EVH
$444M
$4.39M 0.46%
+145,000
New +$4.69M
HCAT icon
60
Health Catalyst
HCAT
$127M
$4M 0.42%
320,000
-20,000
-6% -$238K
TECH icon
61
Bio-Techne
TECH
$11.2B
$3.88M 0.41%
47,500
-7,500
-14% -$603K
NBIX icon
62
Neurocrine Biosciences
NBIX
$16.8B
$3.77M 0.4%
40,000
-30,000
-43% -$2.93M
NUVL
63
DELISTED
Nuvalent
NUVL
$3.63M 0.38%
86,011
-13,989
-14% -$529K
MGTX icon
64
MeiraGTx Holdings
MGTX
$1.21B
$3.62M 0.38%
538,986
– –
WST icon
65
West Pharmaceutical
WST
$24.8B
$3.44M 0.36%
9,000
-6,000
-40% -$2.14M
RVNC
66
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.11M 0.33%
123,000
-107,000
-47% -$3.33M
OLK
67
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$3.11M 0.33%
166,000
-8,300
-5% -$172K
VKTX icon
68
Viking Therapeutics
VKTX
$4.02B
$2.92M 0.31%
180,000
– –
AXSM icon
69
Axsome Therapeutics
AXSM
$11.4B
$2.88M 0.3%
40,100
+25,100
+167% +$1.85M
EW icon
70
Edwards Lifesciences
EW
$53B
$2.74M 0.29%
29,000
-41,000
-59% -$3.56M
RLAY icon
71
Relay Therapeutics
RLAY
$4.37B
$2.39M 0.25%
190,000
– –
BBIO icon
72
BridgeBio Pharma
BBIO
$16.6B
$2.32M 0.24%
135,000
– –
ARVN icon
73
Arvinas
ARVN
$588M
$2.11M 0.22%
85,000
– –
NTLA icon
74
Intellia Therapeutics
NTLA
$1.68B
$2.04M 0.21%
50,000
– –
IMVT icon
75
Immunovant
IMVT
$8.24B
$1.9M 0.2%
+100,000
New +$1.86M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rhenman & Partners Asset Management held 98 positions worth $949M, up 4.1% from $911M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $30.5M in Q2 2023, closing 15 positions and reducing 41 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $8.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Eli Lilly worth $38M.

  • Rhenman & Partners Asset Management's largest Q2 2023 buy was Eli Lilly: 81,000 shares worth $38M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q2 2023, an estimated $14.6M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2023 reduction was Thermo Fisher Scientific, cutting an estimated $21.9M.
  • Rhenman & Partners Asset Management fully exited Silk Road Medical, Inc. Common Stock in Q2 2023, selling an estimated $8.61M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $949M portfolio in Q2 2023.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 15 in Q2 2023.
  • Rhenman & Partners Asset Management's portfolio value rose 4.1% quarter-over-quarter to $949M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.